Abstract 1196P
Background
Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: a population-based study A short title: Regional lymph node metastasis risk factors for rectal neuroendocrine tumors Key words: regional lymph node metastasis, rectal neuroendocrine tumors, SEER, West China Hospital (WCH) databases, tumor size. Purpose: Risk factors for regional lymph node (r-LN) metastasis in rectal neuroendocrine tumors (R-NETs) are still undetermined. We aimed to explore risk factors for patients with r-LN metastatic R-NETs. Information on patients was obtained from the Surveillance, Epidemiology, and End Results (SEER) and West China Hospital (WCH) databases.
Methods
Patients diagnosed with R-NETs between January 2010 and December 2015 from the SEER database composed the construction cohort, while cases from the WCH database were used as the validation cohort. A novel nomogram was constructed to predict r-LN metastasis probability based on a logistic regression model. The performance of the nomogram was internally and externally validated using calibration curves and the concordance index (C-index).
Results
Multivariate logistic analysis identified four poor independent r-LN metastasis factors, including age (≥ 53), differentiation grade (> G1), T stage of primary tumor (> T1) and tumor size (> 1 cm), which we selected as the four risk predictors for nomogram construction. In the internal validation and external validation, the C-index in the internal validation set and the external validation set were 0.968 and 0.877, respectively. The nomogram model was well calibrated, and the ROC curves verified the superiority of our model for clinical usefulness. In addition, the nomogram classification could more accurately differentiate risk subgroups and improve the discrimination of R-NET prognosis.
Conclusions
We developed and validated a prediction risk model of r-LN metastasis for patients with R-NETs. The novel nomogram is a reliable tool to predict the risk of r-LN metastasis, which may assist clinicians in identifying high-risk patients and devising individual treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13